CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 28 enrolled
Drug / intervention
olestradrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01261338
NCT01261338Early Ph 1Completed
CompareCT.gov

Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama

Children's Hospital Medical Center, Cincinnati·interventional·Posted Dec 16, 2010·Updated Sep 14, 2020

In Brief

A Early Phase 1 clinical trial evaluating olestra for Toxic Effect of Other Corrosive Organic Compounds. Completed, enrolled 28 participants across 1 site.

Detailed Summary

Because of industrial pollution, a large number of people in Anniston, Alabama, have elevated body burdens of the class of compounds known as polychlorinated biphenyls (PCBs). There is evidence that these compounds are associated with risks to health including diabetes. There is also evidence that the consumption of a non-absorbable dietary fat can reduce the level of compounds like PCBs. This clinical trial will test the hypothesis that a non-absorbable dietary fat can reduce the levels of PCBs in subjects in Anniston.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsToxic Effect of Other Corrosive Organic Compounds
CountriesUnited States
CollaboratorsNational Institute of Environmental Health Sciences (NIEHS), University of Cincinnati

Timeline

Early Ph 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 16, 2010
Enrollment StartDec 1, 2010
Primary CompletionApr 1, 2012
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.5 years ago

Interventions

olestradrug

non-absorbable dietary fat